Affymetrix Announces Recipients of Its 2014 Tumor Profiling Grant Award to Support Translational Cancer Research
June 18 2014 - 9:02AM
Business Wire
Affymetrix (Nasdaq:AFFX) announces the three recipients who have
been awarded its 2014 Affymetrix Tumor Profiling Grant. The goal of
this grant program is to support translational cancer research in
discovery and analytical validation of biomarkers that may address
current unmet clinical needs in cancer diagnosis, prognosis, and
treatment. Research projects considered for the grant use the
approach of parallel analysis of multiple molecular and cellular
parameters which enables faster identification of the most robust
biomarkers for applications in the clinic with impactful
outcome.
The recipients are:
Dr. Francesco Caiazza, PhD, University College Dublin,
Dublin, IrelandDiscovery and validation of biomarkers of
resistance to Cetuximab in metastatic colorectal cancer
Dr. Aditi Hazra PhD, MPH, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USADiscovery and validation
of genomic and transcriptomic biomarkers associated with rapid
onset of inflammatory breast cancer
Dr. Neetu Singh, PhD, King George's Medical University,
Lucknow, IndiaGenomics and transcriptomics of chronic myeloid
leukemia in North Indians
The high level of interests from researchers around the world
reflects the growing recognition of the value of ‘360° profiling’
of tumor samples. The grant recipients are awarded with Affymetrix’
tools to discover and validate at least two different analytes –
DNA, RNA, or protein – from 30 tumor samples. The cancer types in
these three projects are characterized by rapid onset and poor
survival rates. The discovery of robust biomarkers from each of
these projects has the potential to facilitate better selection of
treatment for each patient, with the goal to increase survival
rates and manage health care costs. “It has been extremely
encouraging to see so many scientists expanding their research to
look beyond just a single parameter to find clinically actionable
cancer biomarkers,” says David Weber, Chief Commercial Officer at
Affymetrix. “This parallel analysis approach increases the
confidence in a newly discovered biomarker, and provides more
biomarker options to take to the clinic. We are delighted that we
can facilitate these selected research projects with a unique set
of tools for analysis of copy number variation, gene expression,
gene regulation, protein- and cellular-changes from biomarker
discovery to clinical applications.”
To learn more about how Affymetrix’ portfolio of solutions for
gene, protein, and cell analysis can accelerate cancer research and
rapidly translate discoveries into routine clinical practice,
please visit www.affymetrix.com/translational.
PLEASE NOTE:
Affymetrix and the Affymetrix logo are trademarks of Affymetrix,
Inc. All other trademarks and product names are the property of
their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales
and distribution operations across Europe, Asia, and
Latin America. For more information about Affymetrix, please
visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
AffymetrixMedia Contact:Mindy Lee-Olsen, 408-731-5523Vice
President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024